Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

Indications for Use of CD34 Selection Column (CliniMACS-Miltenyi Biotec)

Clinical Trial Details

The purpose of this study is to provide cell therapy to you, which will involve the use of CliniMACS CD34 Selection Device. Your family member or an unrelated (donor) will have to undergo a stem cell collection. The donation process that your family member or the unrelated donor will undergo is standard practice. 

The stem cells from the donor will be purified by a procedure called CD34 selection. A special device called the Miltenyi CliniMACS CD34 selection device will be used for this purpose. We have received permission from the FDA and from the producer of the device, the Miltenyi Biotec company, to utilize this device.

You will receive an infusion of the CD34 selected stem cells. These cells are given in a fashion similar to the transfusion of blood and are administered through the central venous catheter.

If successful, the cell infusion will benefit you, by improvement of your white blood cell, platelet and red blood cell counts, or when given as part of stem cell transplant by helping you to be cured of your disease.

Key Eligibility: 
  • Open to men and women above the age of 18 who are in need of an allogeneic transplantation 

Study contact by location

Upper East Side - Manhattan

Contact(s)

Ashlee N. Torres, RN
(212) 746-7117
ant9105@med.cornell.edu

Primary Investigator(s)

Protocol ID(s)

Weill Cornell Medicine IRB #:

1407015348

Status

Open to Enrollment

Sponsor